13 papers in the library · 1,228 citations · publishing 2015-2026
World Psychiatry June 1, 2026 Christina Chwyl, Michael S. Ladka, Joshua C. Black et al.
Prevalence and predictors of sexual and physical violence during psychedelic use in a US population-based study.
World Psychiatry October 1, 2024
Artificial intelligence, consciousness and psychiatry.
World Psychiatry June 1, 2024 Matthew D. Sacchet, Maurizio Fava, Eric L Garland 35 citations
Modulating self-referential processing through meditation and psychedelics: is scientific investigation of self-transcendence clinically relevant?
World Psychiatry January 12, 2024 Marc J. Weintraub, David J. Miklowitz 6 citations
Over the past few years, research and public interest in psychedelic agents – such as psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) – for mental health purposes has skyrocketed. The therapeutic approach to the use of these agents involves three components: preparation, drug administration, and integration. This bundled treatment has been termed psychedelic-assisted therapy (PAT). The...
World Psychiatry September 15, 2023 Roger S McIntyre, Mohammad Alsuwaidan, Bernhard T Baune et al. 712 citations
Treatment‐resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently exist. Instead, a plethora of definitions have been proposed, which vary significantly in their conceptual framework. The absence of a...
World Psychiatry September 15, 2023 Guy M. Goodwin
Interest in the use of serotonergic agonists such as psilocybin in treatment-resistant depression (TRD) has grown more quickly than the evidence on which to base a final opinion, as emphasized by McIntyre et al1 in their review. Psilocybin, once metabolized to psilocin, activates 5-HT2A receptors, enhancing GABA function in local circuits in the cortex and increasing connectivity between...
World Psychiatry January 14, 2023 Oliver Howes, Luke Baxter 16 citations
The US Food and Drug Administration (FDA) approved 12 new drugs in psychiatry during the decade 2011-2021 (www.fda.gov/drugs/drug-approvals-and-databases). In comparison, it approved 50 new drugs in neurology and 135 in oncology over the same period. The FDA designated two new drugs as first-in-class in psychiatry (lofexidine and brexanolone) in the most recent reviewed period (2015-2021),...
World Psychiatry June 1, 2022
Subjectivity, psychosis and the science of psychiatry.
World Psychiatry May 18, 2021 Wayne Hall 17 citations
A psychedelic drug is one that “produces thought, mood and perceptual changes otherwise rarely experienced except in dreams, contemplative and religious exaltation, flashes of vivid involuntary memory, and acute psychosis”1. It does so “without causing physical addiction, craving, major physiological disturbances, delirium, disorientation or amnesia”1. The “classic psychedelics” include...
World Psychiatry September 7, 2018 Robin Carhart-Harris 49 citations
Serotonin is a key neuromodulator known to be involved in brain development, perception, cognition, and mood. However, unlike as with dopamine for example, a compelling unified theory of brain serotonin function has not yet been established. This is likely due to the exceptional complexity of the serotonin system, with its 14+ receptors, over twice the number identified for any of the other...
World Psychiatry September 22, 2016 Zindel V. Segal, Lê-Anh Dinh-Williams 11 citations
Relapse and recurrence are common and debilitating aspects of major depressive disorder. Furthermore, the risk of developing a chronic course of illness increases with each successive episode and, even among patients who achieve clinical remission, residual depressive symptoms are commonly reported. Maintenance antidepressant monotherapy is effective as long as it is continued, yet in practice...
World Psychiatry February 1, 2016 Fabrizio Schifano, Laura Orsolini, Gabriele Duccio Papanti et al. 319 citations
Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a range of prescribedmedications, psychoactive plants/herbs, and a large series of performance and image enhancing drugs. Users are typically...
World Psychiatry September 25, 2015 Carlos A. Zarate, Mark J. Niciu 63 citations
Major depressive disorder and bipolar depression are among the most prevalent and disabling mental disorders worldwide. Real-world effectiveness trials in major depressive disorder have underscored that most pharmacological options target monoamines, which are involved in a minority (15-20%) of synaptic contacts in the mammalian brain. Most synapses (∼50%) use the amino acid glutamate as their...